| 1 Proportion of participants with ≥ 1 adverse events considered 'not to be serious' – overall |
2 |
240 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.02, 11.98] |
| 2 Proportion of participants with ≥ 1 adverse events considered 'not to be serious' – concomitant disease |
2 |
240 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.02, 11.98] |
| 2.1 Participants diagnosed with only chronic hepatitis B |
1 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.08 [0.00, 1.34] |
| 2.2 Participants diagnosed with concomitant diseases |
1 |
80 |
Risk Ratio (M‐H, Random, 95% CI) |
2.0 [0.19, 21.18] |
| 3 Proportion of participants with detectable HBV‐DNA in serum or plasma – overall |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 4 Proportion of participants with detectable HBV‐DNA in serum or plasma – incomplete data |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 4.1 Trials at low risk of bias |
2 |
143 |
Risk Ratio (M‐H, Random, 95% CI) |
0.49 [0.28, 0.87] |
| 4.2 Trials at high risk of bias |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.69 [0.47, 1.01] |
| 5 Proportion of participants with detectable HBV‐DNA in serum or plasma – formula type |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 5.1 Experimental intervention with traditional XCHT formula |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.51 [0.28, 0.95] |
| 5.2 Experimental intervention with modified XCHT formula |
2 |
141 |
Risk Ratio (M‐H, Random, 95% CI) |
0.66 [0.45, 0.96] |
| 6 Proportion of participants with detectable HBV‐DNA in serum or plasma – forms |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 6.1 Water extraction of XCHT formula |
2 |
143 |
Risk Ratio (M‐H, Random, 95% CI) |
0.49 [0.28, 0.87] |
| 6.2 Granule of XCHT |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.69 [0.47, 1.01] |
| 7 Proportion of participants with detectable HBV‐DNA in serum or plasma – duration |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 7.1 Duration < 6 months |
1 |
62 |
Risk Ratio (M‐H, Random, 95% CI) |
0.39 [0.09, 1.62] |
| 7.2 Duration > 6 months |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.63 [0.46, 0.88] |
| 8 Proportion of participants with detectable HBV‐DNA in serum or plasma – dosage |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 8.1 XCHT < 15 g |
2 |
141 |
Risk Ratio (M‐H, Random, 95% CI) |
0.66 [0.45, 0.96] |
| 8.2 XCHT > 15 g |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.51 [0.28, 0.95] |
| 9 Proportion of participants with detectable HBV‐DNA in serum or plasma – diagnostic criteria |
3 |
222 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.45, 0.85] |
| 9.1 Participants with diagnostic criteria according to guidelines |
2 |
141 |
Risk Ratio (M‐H, Random, 95% CI) |
0.66 [0.45, 0.96] |
| 9.2 Participants with diagnosis by trialists |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.51 [0.28, 0.95] |
| 10 Proportion of participants with detectable HBeAg in serum or plasma in fixed‐effect model – overall |
2 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.70 [0.55, 0.91] |
| 11 Proportion of participants with detectable HBeAg in serum or plasma in random‐effects model – overall |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.50, 1.02] |
| 12 Proportion of participants with detectable HBeAg in serum or plasma – incomplete data |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.50, 1.02] |
| 12.1 Trials at low risk of bias |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.56 [0.32, 0.97] |
| 12.2 Trials at high risk of bias |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.62, 1.03] |
| 13 Proportion of participants with detectable HBeAg in serum or plasma – formula type |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.50, 1.02] |
| 13.1 Experimental intervention with traditional XCHT formula |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.56 [0.32, 0.97] |
| 13.2 Experimental intervention with modified XCHT formula |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.62, 1.03] |
| 14 Proportion of participants with detectable HBeAg in serum or plasma – forms |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.50, 1.02] |
| 14.1 Water extraction of XCHT formula |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.56 [0.32, 0.97] |
| 14.2 Granule of XCHT |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.62, 1.03] |
| 15 Proportion of participants with detectable HBeAg in serum or plasma – duration |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.50, 1.02] |
| 15.1 Duration < 6 months |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.62, 1.03] |
| 15.2 Duration > 6 months |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.56 [0.32, 0.97] |
| 16 Proportion of participants with detectable HBeAg in serum or plasma – dosage |
2 |
160 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.50, 1.02] |
| 16.1 XCHT < 15 g |
1 |
79 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.62, 1.03] |
| 16.2 XCHT > 15 g |
1 |
81 |
Risk Ratio (M‐H, Random, 95% CI) |
0.56 [0.32, 0.97] |
| 17 Proportion of participants with nausea |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 18 Proportion of participants with nausea and vomiting |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 19 Proportion of participants with dizziness and sleep disorders |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 20 Proportion of participants with dizziness and fatigue |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 21 Proportion of participants with a dry feeling or bitter taste in the mouth |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 22 Proportion of participants with bloating and belching |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 23 Proportion of participants with loss of appetite |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
